PEDAL THE CAUSE

Financials

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

Address and contacts

Address (IRS master file)

9288 DIELMAN INDUSTRIAL DR, SAINT LOUIS, MO 63132-2203

In care of

% PAUL VOGEL

Principal officer (990 for 2025)

DAVID DRIER, 9288 DIELMAN INDUSTRIAL DRIVE, ST LOUIS, MO 63132

Signed the 990

DAVID DRIER, EXECUTIVE DIRECTOR

Phone

(314) 787-1990

Website

WWW.PEDALTHECAUSE.ORG

Return prepared by

ARMANINO ADVISORY LLC

Mission

OUR MISSION IS TO PROVIDE FUNDING FOR CANCER RESEARCH AT SITEMAN CANCER CENTER AND SITEMAN KIDS AT ST. LOUIS CHILDREN'S HOSPITAL THROUGH OUR ANNUAL CYCLE CHALLENGE. IT IS OUR HOPE THAT RESEARCH FUNDED BY PEDAL THE CAUSE WILL ULTIMATELY LEAD TO A CURE FOR CANCER.

Program accomplishments

• IN 2025, OVER 3,800 ADULTS AND CHILDREN PARTICIPATED IN PEDAL THE CAUSE, SUPPORTED BY 700 VOLUNTEERS, WHO TOGETHER RAISED OVER $5.0 MILLION TO FUND CANCER RESEARCH. OVER THE PAST 16 YEARS, PEDAL THE CAUSE HAS CUMULATIVELY DONATED $56 MILLION SUPPORTING 255 ADULT AND PEDIATRIC CANCER RESEARCH PROJECTS. FOR EVERY $1 PEDAL THE CAUSE DONATES TO CANCER RESEARCH, RESEARCHERS HAVE SUCCESSFULLY ATTRACTED SIGNIFICANT ADDITIONAL EXTERNAL FUNDING TO FURTHER THEIR RESEARCH, AVERAGING $14 FOR EVERY $1 INITIAL AWARD. IN 2025, PEDAL THE CAUSE EFFECTIVELY DISTRIBUTED 85% OF ITS REVENUE TO PROGRAM SERVICES. (CONTINUED ON SCHEDULE O)MAJOR BREAKTHROUGHS MADE POSSIBLE BY PEDAL THE CAUSE FUNDS INCLUDE THE DEVELOPMENT OF DNA AND PEPTIDE VACCINES FOR MULTIPLE CANCER TYPES, CANCER GOOGLES TO HELP SURGEONS SEE CANCER CELLS, IMMUNOTHERAPY HARNESSING OUR BODY'S 'NATURAL KILLER' CELLS AND CUTTING-EDGE RESEARCH IN THE UNDERSTANDING OF CANCER STEM-CELLS. PEDAL THE CAUSE FUNDS HAVE BEEN INSTRUMENTAL IN OBTAINING SPORE (SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE) GRANTS IN LEUKEMIA AND PANCREATIC CANCER, WHICH LEAD A NATIONAL GROUP OF EXPERTS IN COLLABORATIVE RESEARCH. PEDAL THE CAUSE FUNDED CLINICAL TRIALS ARE A KEY COMPONENT OF THE ROBUST CLINICAL TRIAL PROGRAM AT SITEMAN CANCER CENTER, WHICH RANKS AS THE LARGEST CANCER CLINICAL TRIALS PROGRAM IN THE MIDWEST AND THIRD LARGEST IN THE COUNTRY. SIGNIFICANT 2025 EXTERNAL FUNDING INCLUDED:LUNG CANCER & SMOKING CESSATIONLI-SHIUN CHEN, MD, MPH, SCD AND AIMEE JAMES, PHD, MPH RECEIVED A SIP RDA AWARD IN 2020 FOR THEIR PROJECT, "IMPLEMENTING MULTILEVEL SMOKING CESSATION INTERVENTIONS TO REDUCE RURAL CANCER DISPARITY." THEIR RESEARCH AIMED TO REDUCE THE HIGH SMOKING RATES AND ASSOCIATED CANCER DISPARITIES IN RURAL SOUTHERN ILLINOIS BY DEVELOPING A MULTI-LEVEL APPROACH TO HELP PATIENTS QUIT SMOKING. WITH PEDAL THE CAUSE SUPPORT, THE TEAM CREATED A COST-EFFECTIVE SMOKING CESSATION MODEL THAT CONNECTED TWO TO THREE TIMES MORE PATIENTS WITH TREATMENT AND ACHIEVED THREE TIMES GREATER QUIT SUCCESS THAN PREVIOUS APPROACHES, IMPROVING CANCER PREVENTION EFFORTS ACROSS RURAL COMMUNITIES. BUILDING ON THESE RESULTS, THE TEAM LEVERAGED THEIR WORK INTO A PRESTIGIOUS SIX-YEAR UG3/UH3 AWARD FROM THE NATIONAL CANCER INSTITUTE (NCI) TO EXPAND PRECISION TOBACCO TREATMENT FOR CANCER SURVIVORS. $6.7 MILLION IN NATIONAL CANCER INSTITUTE FUNDING RECEIVED IN 2025. HEMATOLOGIC/BLOOD CANCERYOON-A KANG, PHD RECEIVED A SIP RDA AWARD IN 2025 FOR HER PROJECT, "TARGETING MYELOID-BIASED MULTIPOTENT PROGENITOR TO REBALANCE LINEAGE OUTPUT IN MPNS." THE PROJECT FOCUSES ON DEVELOPING A NEW TREATMENT STRATEGY FOR MYELOPROLIFERATIVE NEOPLASMS (MPNS) BY TARGETING MULTIPOTENT PROGENITOR 3 (MPP3) CELLS, WHICH PLAY A KEY ROLE IN THE OVERPRODUCTION OF BLOOD CELLS SEEN IN THESE CANCERS. DR. KANG'S RESEARCH IS INVESTIGATING HOW REGULATING MPP3 BLOOD CELL PRODUCTION MECHANISMS COULD FORM THE FOUNDATION OF A BROADLY EFFECTIVE THERAPY FOR MPN PATIENTS REGARDLESS OF THEIR SPECIFIC GENETIC MUTATION. $860,000 IN AMERICAN CANCER SOCIETY FUNDING TO BE RECEIVED IN 2026. BREAST & OVARIAN CANCER PREVENTIONJOHN KRAIS, PHD RECEIVED A SIP RDA AWARD IN 2024 FOR HIS PROJECT, "TMEJ AND BRCA1 MUTANT TUMOR DEVELOPMENT." HIS RESEARCH INVESTIGATES HOW DNA DAMAGE ACCUMULATES AND IS REPAIRED IN CELLS CARRYING BRCA1 MUTATIONS, WITH THE GOAL OF PREVENTING THESE HIGH-RISK CELLS FROM BECOMING CANCEROUS. BY STUDYING A DNA REPAIR PATHWAY KNOWN AS POLYMERASE THETA-MEDIATED END JOINING (TMEJ), DR. KRAIS IS LAYING THE GROUNDWORK FOR A POTENTIAL NEW CANCER PREVENTION STRATEGY FOR INDIVIDUALS WITH INHERITED BRCA1 AND BRCA2 MUTATIONS. THE PROMISING PRELIMINARY DATA GENERATED THROUGH PEDAL THE CAUSE FUNDING LED TO MULTIPLE COMPETITIVE RESEARCH AWARDS THAT WILL ACCELERATE THIS WORK TOWARD FUTURE CLINICAL APPLICATIONS. $2.45 MILLION IN EXTERNAL FUNDING RECEIVED IN 2025, INCLUDING AN R35 AWARD FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES, AN OVARIAN CANCER RESEARCH FUND AWARD, AND A CANCER RESEARCH FOUNDATION GRANT. CHEMOTHERAPY SIDE EFFECTS & HEART HEALTHNIMA MOSAMMAPARAST, MD, PHD AND KORY LAVINE, MD, PHD RECEIVED A SIP RDA AWARD IN 2019 FOR THEIR PROJECT, "ALKYLATING CHEMOTHERAPIES PROMOTE HEART FAILURE BY TARGETING TISSUE RESIDENT CARDIAC MACROPHAGES." THEIR RESEARCH EXAMINED WHY COMMONLY USED CHEMOTHERAPY DRUGS CAN CAUSE LONG-TERM HEART DAMAGE IN CANCER SURVIVORS. THE TEAM DISCOVERED THAT DIFFERING RESPONSES IN HEALTHY TISSUES ARE A MAJOR CONTRIBUTOR TO THESE LASTING SIDE EFFECTS, CREATING NEW OPPORTUNITIES TO REDUCE TREATMENT-RELATED HEART FAILURE WHILE PRESERVING THE EFFECTIVENESS OF CANCER THERAPIES. THESE DISCOVERIES ALSO OPENED NEW AVENUES OF INVESTIGATION INTO HOW RNA DAMAGE CONTRIBUTES TO GENOMIC INSTABILITY. $850,000 IN NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) R01 FUNDING RECEIVED IN 2025. CHEMOTHERAPY & RNA DAMAGENIMA MOSAMMAPARAST, MD, PHD AND HANI ZAHER, PHD RECEIVED A SIP RDA AWARD IN 2017 FOR THEIR PROJECT, "RNA AS A TARGET OF ALKYLATION CHEMOTHERAPY IN CANCER." THEIR WORK FUNDAMENTALLY CHANGED THE UNDERSTANDING OF HOW CHEMOTHERAPY DAMAGES RNA WITHIN CELLS AND HOW THAT DAMAGE INFLUENCES TUMOR RESPONSE TO TREATMENT. THE FINDINGS HAVE BEEN PUBLISHED IN NUMEROUS HIGH-IMPACT SCIENTIFIC JOURNALS, INCLUDING NATURE AND MOLECULAR CELL, AND CONTINUE TO SHAPE NEW APPROACHES FOR IMPROVING CHEMOTHERAPY EFFECTIVENESS ACROSS MULTIPLE CANCER TYPES. BUILDING ON THESE DISCOVERIES, THE TEAM SECURED ANOTHER MAJOR FEDERAL RESEARCH AWARD TO FURTHER INVESTIGATE THE CONNECTION BETWEEN INNATE IMMUNE SIGNALING AND CANCER THERAPY. $2.5 MILLION IN NATIONAL INSTITUTES OF HEALTH R01 FUNDING WAS RECEIVED IN 2024. BREAST CANCER METASTASISAMIT PATHAK, PHD RECEIVED A SIP RDA AWARD IN 2017 FOR HIS PROJECT, "MEMORY-PLASTICITY CROSSTALK IN CANCER CELLS." HIS RESEARCH EXPLORED WHETHER INVASIVE BREAST CANCER CELLS RETAIN A "MEMORY" OF THE PHYSICAL ENVIRONMENT OF THEIR ORIGINAL TUMOR, A DISCOVERY THAT COULD EXPLAIN HOW METASTATIC TUMORS SPREAD THROUGHOUT THE BODY. THE PROJECT EXPANDED INTO ANIMAL STUDIES AND COMPUTATIONAL MODELING TO IDENTIFY GENE TARGETS CAPABLE OF SLOWING OR PREVENTING METASTASIS. THESE FINDINGS HAVE CONTINUED TO GROW INTO BROADER STUDIES EXAMINING HOW CELLS ADAPT TO CHANGES IN THEIR PHYSICAL ENVIRONMENT AND HOW THOSE CHANGES CONTRIBUTE TO DISEASE. $2.1 MILLION IN NATIONAL INSTITUTES OF HEALTH R35 FUNDING RECEIVED IN 2025. GASTRIC CANCER IMMUNOTHERAPYPATRICIA RIBEIRO PEREIRA, PHD RECEIVED A SIP RDA AWARD IN 2022 FOR HER PROJECT, "THE ROLE OF CAVEOLIN-1 IN GASTRIC CANCER RESPONSE TO IMMUNOTHERAPY." THE PROJECT SOUGHT TO IMPROVE IMMUNOTHERAPY FOR STOMACH CANCER BY USING ADVANCED PET IMAGING TO BETTER UNDERSTAND HOW TUMORS RESPOND TO TREATMENT. DR. PEREIRA'S TEAM DISCOVERED THAT THE PROTEIN CAVEOLIN-1 CAN HIDE TUMOR TARGETS FROM IMMUNOTHERAPIES, LEADING TO THE DEVELOPMENT OF NEW STRATEGIES TO MAKE THESE TREATMENTS MORE EFFECTIVE. THE PROJECT HAS PRODUCED MULTIPLE SCIENTIFIC PUBLICATIONS AND CONTINUES TO ADVANCE RESEARCH INTO IMPROVING IMMUNOTHERAPY FOR BOTH GASTRIC AND BREAST CANCERS. NATIONAL INSTITUTES OF HEALTH/NATIONAL CANCER INSTITUTE R37 MERIT FUNDING RECEIVED IN 2023 TO EXPAND THIS RESEARCH. PROSTATE & PEDIATRIC CANCERHANWEN ZHANG, PHD RECEIVED A SIP RDA AWARD IN 2023 FOR HIS PROJECT, "NEXT GENERATION THERANOSTIC 89ZR/227TH-CONJUGATED PSMA INHIBITOR FOR PRECISION MOLECULAR IMAGING AND RADIOTHERAPY OF METASTATIC PROSTATE CANCER." HIS RESEARCH IS DEVELOPING A NEXT-GENERATION RADIOTRACER CAPABLE OF BOTH DETECTING AND TREATING METASTATIC PROSTATE CANCER WITH GREATER PRECISION. EARLY STUDIES HAVE DEMONSTRATED STRONG RESULTS IN ANIMAL MODELS, PAVING THE WAY FOR FDA APPROVAL AND FUTURE HUMAN CLINICAL TRIALS. THE TECHNOLOGY HAS ALSO SHOWN PROMISE BEYOND PROSTATE CANCER, LEADING TO EXPANSION INTO PEDIATRIC NEUROBLASTOMA RESEARCH. $3 MILLION IN NATIONAL CANCER INSTITUTE R01 FUNDING WAS RECEIVED IN 2024.
  Expenses $6,583,079 · grants $5,042,167 · revenue $333,913

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

IRS record

EIN

27-2233336

Tax-exempt status

501(c)(3): Charitable, religious, educational or scientific organization

Foundation status

Publicly supported organization (170(b)(1)(A)(vi))

Donations deductible (Pub 78)

Public charity, 50% deduction limit

Exempt since

2010

Accounting year ends

December

Files

Form 990 or 990-EZ

Category (NTEE)

Human services (P20)

Assets (IRS master file)

$2,750,782

Income (IRS master file)

$7,465,739

Filing history

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 27-2233336).

Questions about PEDAL THE CAUSE

What is the EIN of PEDAL THE CAUSE?

The employer identification number (EIN) of PEDAL THE CAUSE is 27-2233336.

Is PEDAL THE CAUSE tax-exempt?

Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2010.

Are donations to PEDAL THE CAUSE tax-deductible?

Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).

Which annual return does PEDAL THE CAUSE file?

Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.

When is the next return of PEDAL THE CAUSE due?

The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.

When did PEDAL THE CAUSE last file with the IRS?

The latest return in the IRS public files is the 990 for the year ended December 2025.

Who is the principal officer of PEDAL THE CAUSE?

The 990 for the year ended December 31, 2025 names DAVID DRIER.

Who are the officers and directors of PEDAL THE CAUSE?

The 990 for the year ended December 31, 2025 lists 37 people; 5 received compensation from the organization, the highest $236,766 (DAVID DRIER, EXECUTIVE DIRECTOR).

How much revenue does PEDAL THE CAUSE have?

On its 990 for the year ended December 31, 2025 it reported revenue of $7,338,892, expenses of $7,752,943 and total assets of $2,750,782 at year end.

Other nonprofits in SAINT LOUIS

• PRESENCE CHICAGO HOSPITALS NETWORK
  EIN 36-2235165 · last filed 990 for 2025
• LUTHERAN SENIOR SERVICES
  EIN 43-0654862 · last filed 990 for 2024
• MERS MISSOURI GOODWILL INDUSTRIES
  EIN 43-0652657 · last filed 990 for 2024
• GATEWAY REGION YOUNG MENS CHRISTIAN ASSOCIATION
  EIN 43-0653616 · last filed 990 for 2025
• FRIENDSHIP VILLAGE OF SOUTH COUNTY
  EIN 43-1155242 · last filed 990 for 2025
• ST LOUIS ARC INC
  EIN 43-0718811 · last filed 990 for 2025
• INTERNATIONAL INSTITUTE OF METROPOLITAN ST LOUIS
  EIN 43-0652640 · last filed 990 for 2024
• ASCENSION LIVING ALEXIAN VILLAGE TENNESEE
  EIN 62-1136742 · last filed 990 for 2025

All nonprofits in SAINT LOUIS · Missouri · Human services